Trial Profile
A phase I trial of GKT 137831 for diabetic nephropathy in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2012
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Pharmacokinetics
- 02 Nov 2012 Results have been reported in a Gekyotex media release.
- 02 Nov 2012 Status changed from active, no longer recruiting to completed based on information reported in a Genkyotex media release.
- 02 Nov 2012 Results have been presented at Kidney Week 2012, the annual meeting of the American Society of Nephrology, according to a Genkyotex media release. Results were also summarised in the media release.